In 2022, Steve Krognes earned $173.75K in total compensation at Pliant Therapeutics, primarily from $167.07K salary. Most recently sold 3,454 shares in Aug 2024. Currently holds stock worth $19.80M. 1+ years at the helm of Pliant Therapeutics.
Compensation History
Annual executive compensation data for Steve Krognes, including salary, bonuses, and stock awards.
Year
2022
Total Compensation
$173.75K
Salary
$167.07K
Bonus
$0.00
Other
$6.68K
Salary
$167.07KBoard Justification
The compensation philosophy focuses on pay for performance and alignment with stockholder interests.
Bonus
$0.00Board Justification
No annual bonus was earned for 2022 due to transition to non-employee director role.
Other Compensation
$6.68KBoard Justification
This includes employer 401(k) matching contributions paid to Mr. Krognes.
Restricted Stock
Board Justification
No stock awards vested in 2022 as all stock and option awards granted during the year were forfeited upon transition.
Performance Metrics
Performance metrics for bonuses were based on achievement of corporate goals, but no bonus was earned due to transition.
Steve Krognes
CEO of Pliant Therapeutics
Sector of Economy
Healthcare
CEO of Pliant Therapeutics for
1 year 5 months (Jun 2024 - Present)
Previous Experience
Experienced in corporate governance and audit
Holdings
Track Steve Krognes's stock holdings and portfolio value over time.
Total Stock Sold
$13.68M
$13.68M
307,015 DNLI shares
What if they kept their stock?
If Steve Krognes didn't sell their stock, today they would have:
Extra DNLI307,015 shares worth $6.13M.
This is -55.22% and $7.56M less than what they got when they sold the stock.
Insider Trading
Steve Krognes's recent stock transactions, purchases, and sales filed with the SEC.
$82.17K
DNLI at $23.79/share
Aug 20, 2024
Sale
$682.40K
DNLI at $22.24/share
Jun 13, 2024
Sale
5,967 shares
DNLI
May 31, 2024
Received
$1.90M
DNLI at $20.50/share
Apr 1, 2024
Sale
$47.55K
DNLI at $17.29/share
Feb 13, 2024
Sale
$62.33K
DNLI at $19.43/share
Jan 5, 2024
Sale
$32.07K
DNLI at $22.60/share
Aug 21, 2023
Sale
4,216 shares
DNLI
Jun 1, 2023
Received
$63.78K
DNLI at $30.10/share
Feb 13, 2023
Sale
$42.52K
DNLI at $30.88/share
Feb 8, 2023
Sale
Rivals
Compare Steve Krognes with competitor CEOs and industry peers.